Abstract
In the last decade several attempts have been made to achieve the goal of cardiac regeneration after myocardial infarction. To date, two cell types have completed phase-III clinical trials: Skeletal Myoblasts and Bone-Marrow Mononuclear Cells (BM-MNCs). In the first case, all benefits have been limited by an increased risk of arrhythmia. In the case of BM-cells, most studies showed a significant, although limited, advantage in the cell-treated group. This may be due to the choice of the wrong BM cell type: other candidates would be e.g. CD34+ HSCs, or non-hematopoietic Mesenchymal Stem Cells. After positive results from the experimental studies, phase I/II clinical trials are currently on-going for both.
Ideally, the best cell to use to regenerate the heart would be a precursor of all cardiac lineages; until the isolation and expansion of Cardiac Stem Cells (CSCs), such a cell was thought to exist only during embryogenesis. Using CSCs researchers managed to generate electrically-coupled contractile tissue within the infarct of animal models. Still, some doubts persist over the possibility to translate such results in real-life patients.
Another approach, therefore, involves the use of induced Pluripotent Stem Cells (iPS) obtained from fibroblasts after genetic reprogramming. This new type of cell would combine the pluripotency of embryonal stem cells with the advantages of an autologous use. Nevertheless, iPS cells form teratomas, and their effective differentiation in vivo is largely unknown.
This review will critically compare the data from the Literature concerning cell therapy after myocardial infarction. Can we name the best cell?
Keywords: Adult stem cells, cardiac regeneration, cell therapy, bone marrow, mesenchymal stem cells, cardiac stem cells, induced pluripotent stem cells, acute myocardial infarction
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Cell Therapy for Cardiac Regeneration after Myocardial Infarct: Which Cell is the Best?
Volume: 8 Issue: 4
Author(s): Federico Mosna, Francesco Annunziato, Giovanni Pizzolo and Mauro Krampera
Affiliation:
Keywords: Adult stem cells, cardiac regeneration, cell therapy, bone marrow, mesenchymal stem cells, cardiac stem cells, induced pluripotent stem cells, acute myocardial infarction
Abstract: In the last decade several attempts have been made to achieve the goal of cardiac regeneration after myocardial infarction. To date, two cell types have completed phase-III clinical trials: Skeletal Myoblasts and Bone-Marrow Mononuclear Cells (BM-MNCs). In the first case, all benefits have been limited by an increased risk of arrhythmia. In the case of BM-cells, most studies showed a significant, although limited, advantage in the cell-treated group. This may be due to the choice of the wrong BM cell type: other candidates would be e.g. CD34+ HSCs, or non-hematopoietic Mesenchymal Stem Cells. After positive results from the experimental studies, phase I/II clinical trials are currently on-going for both.
Ideally, the best cell to use to regenerate the heart would be a precursor of all cardiac lineages; until the isolation and expansion of Cardiac Stem Cells (CSCs), such a cell was thought to exist only during embryogenesis. Using CSCs researchers managed to generate electrically-coupled contractile tissue within the infarct of animal models. Still, some doubts persist over the possibility to translate such results in real-life patients.
Another approach, therefore, involves the use of induced Pluripotent Stem Cells (iPS) obtained from fibroblasts after genetic reprogramming. This new type of cell would combine the pluripotency of embryonal stem cells with the advantages of an autologous use. Nevertheless, iPS cells form teratomas, and their effective differentiation in vivo is largely unknown.
This review will critically compare the data from the Literature concerning cell therapy after myocardial infarction. Can we name the best cell?
Export Options
About this article
Cite this article as:
Mosna Federico, Annunziato Francesco, Pizzolo Giovanni and Krampera Mauro, Cell Therapy for Cardiac Regeneration after Myocardial Infarct: Which Cell is the Best?, Cardiovascular & Hematological Agents in Medicinal Chemistry 2010; 8 (4) . https://dx.doi.org/10.2174/187152510792481216
DOI https://dx.doi.org/10.2174/187152510792481216 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Interferon-Alpha in the Treatment of Multiple Myeloma
Current Drug Targets Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem
Current Cardiology Reviews Beta-blockers in the Perioperative Period: Are there Indications other than Prevention of Cardiac Ischemia?
Current Drug Targets The Fundamental Basis of Palpitations: A Neurocardiology Approach
Current Cardiology Reviews Editorial [Hot Topic: The Endothelin System: Vascular Targets for Therapy in Disease (Guest Editor: Michael R. Dashwood)]
Current Vascular Pharmacology Advances in Drug Safety
Current Pharmaceutical Design Perinatal and Neonatal Outcomes of Lithium-Treated and Untreated Bipolar Women During Pregnancy: A Review of Present Literature
Current Psychopharmacology Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome
Current Signal Transduction Therapy Weaning and Extubation in Pediatrics
Current Respiratory Medicine Reviews Drug Induced QT Prolongation: Lessons from Congenital and Acquired Long QT Syndromes
Current Drug Targets - Cardiovascular & Hematological Disorders The Role of Myocardial Collagen Network in Hypertensive Heart Disease
Current Hypertension Reviews Antihypertensive Treatments in Patients Affected by Aortic Valve Stenosis
Current Pharmaceutical Design Adverse Systemic Reactions of Antihistamines: Highlights in Sedating Effects, Cardiotoxicity and Drug Interactions
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Regulation of Intracellular Cardiomyocyte Calcium Stores by Peptides: A New Approach to Cardiac Protection
Current Medicinal Chemistry Alert Cell Strategy: Mechanisms of Inflammatory Response and Organ Protection
Current Pharmaceutical Design Heart Failure Pharmacotherapy: Differences Between Adult and Paediatric Patients
Current Medicinal Chemistry Xenosensors CAR and PXR at Work: Impact on Statin Metabolism
Current Drug Metabolism A Perspective on Quantum Mechanics Calculations in ADMET Predictions
Current Topics in Medicinal Chemistry Cardiac Output by Flotrac/VigileoTM Validation Trials: Are there Reliable Conclusions?
Reviews on Recent Clinical Trials Mitochondrial Therapeutics for Cardioprotection
Current Pharmaceutical Design